The GlaxoSmithKline plc (GSK) Price Target Raised to GBX 1,780 at Jefferies Group

The GlaxoSmithKline plc (GSK) Price Target Raised to GBX 1,780 at Jefferies Group

GlaxoSmithKline plc (LON:GSK) had its price objective hoisted by Jefferies Group from GBX 1,750 ($21.11) to GBX 1,780 ($21.47) in a research note released on Sunday, StockTargetPrices.com reports. Jefferies Group currently has a buy rating on the stock.

GSK has been the topic of a number of other research reports. Citigroup Inc. restated a buy rating on shares of GlaxoSmithKline plc in a research note on Monday, November 7th. Bryan, Garnier & Co restated a buy rating and issued a GBX 1,850 ($22.32) target price on shares of GlaxoSmithKline plc in a research note on Monday, January 9th. BNP Paribas restated an underperform rating and issued a GBX 1,520 ($18.34) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, December 21st. JPMorgan Chase & Co. restated a neutral rating and issued a GBX 1,600 ($19.30) target price on shares of GlaxoSmithKline plc in a research note on Thursday, January 12th. Finally, Deutsche Bank AG upped their target price on GlaxoSmithKline plc from GBX 1,760 ($21.23) to GBX 1,800 ($21.72) and gave the stock a hold rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of GBX 1,729.13 ($20.86).

GlaxoSmithKline plc (LON:GSK) opened at 1546.50 on Friday. The firm’s 50-day moving average price is GBX 1,535.16 and its 200 day moving average price is GBX 1,608.71. GlaxoSmithKline plc has a 12-month low of GBX 1,314.26 and a 12-month high of GBX 1,745.56. The stock’s market cap is GBX 75.25 billion.

The business also recently announced a dividend, which was paid on Thursday, January 12th. Investors of record on Thursday, November 3rd were issued a GBX 19 ($0.23) dividend. The ex-dividend date was Thursday, November 3rd. This represents a yield of 1.17%.

In related news, insider Moncef Slaoui bought 58 shares of the firm’s stock in a transaction that occurred on Monday, January 9th. The stock was purchased at an average cost of GBX 1,972 ($23.79) per share, for a total transaction of £1,143.76 ($1,379.85). Also, insider Sir Andrew P. Witty sold 10,000 shares of GlaxoSmithKline plc stock in a transaction on Thursday, October 27th. The shares were sold at an average price of GBX 1,636 ($19.74), for a total value of £163,600 ($197,370.01). Over the last quarter, insiders purchased 1,838 shares of company stock valued at $3,038,584.

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Related posts

Leave a Comment